# Pariglasgene brecaparvovec PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pariglasgene-brecaparvovec

> Pariglasgene brecaparvovec, sponsored by Ultragenyx Pharmaceutical Inc. (RARE): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | pariglasgene brecaparvovec |
| Codes | DTX401 |
| Sponsor | Ultragenyx Pharmaceutical Inc. (RARE) https://sec-api.dev/companies/rare/catalysts |
| Indications | [glycogen storage disease type ia](https://sec-api.dev/indications/glycogen-storage-disease-type-ia), aged eight years and older |
| Modality | gene_therapy |
| FDA designations | accelerated, fast track, orphan, rmat |

## Timeline

### May 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: aged eight years and older.
- First seen 2025-02-19, last confirmed 2025-02-19.
- SEC Form 10-K (accession 0000950170-25-023312): "In May 2024, we announced positive topline results from our Phase 3 GlucoGene study for the treatment of patients aged eight years and older." https://www.sec.gov/Archives/edgar/data/1515673/000095017025023312/rare-20241231.htm

### Q4 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-01-13, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-103026): "DTX401 AAV gene therapy for Glycogen Storage Disease Type Ia (GSDIa): BLA submission expected in the fourth quarter of 2025" https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/rare-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-264707): "Rolling submission of the BLA is expected to complete in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/rare-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-064473): "DTX401 AAV gene therapy for Glycogen Storage Disease Type Ia (GSDIa): BLA submission expected in mid-2025" https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-019854): "These results have been discussed with regulatory authorities in a pre-BLA meeting and will be included as part of a BLA submission in mid-2025." https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/rare-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-004587): "These results have been discussed with regulatory authorities in a pre-BLA meeting and will be included as part of a BLA submission in mid-2025." https://www.sec.gov/Archives/edgar/data/1515673/000095017025004587/rare-ex99_1.htm

### February 23, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: Glycogen Storage Disease Type Ia.
- First seen 2026-02-23, last confirmed 2026-08-05.
- SEC Form 10-Q (accession 0001193125-26-333233): "In February 2026, we announced that the FDA has accepted for review the Biologics License Application, or BLA, seeking approval of DTX401 for the treatment of Glycogen Storage Disease Type Ia (GSDIa)." https://www.sec.gov/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-206960): "In February 2026, we announced that the FDA has accepted for review the BLA seeking approval of DTX401 for the treatment of Glycogen Storage Disease Type Ia (GSDIa)." https://www.sec.gov/Archives/edgar/data/1515673/000119312526206960/rare-20260331.htm
- SEC Form 8-K (accession 0001193125-26-062568): "On February 23, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for review the Biologics License Application (the "BLA") seeking approval of DTX401 AAV gene therapy (pariglasgene brecaparvovec) for the treatment of Glycogen Storage Disease Type Ia (GSDIa)." https://www.sec.gov/Archives/edgar/data/1515673/000119312526062568/rare-20260223.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-332802): "DTX401 (pariglasgene brecaparvovec) AAV8 gene therapy for the treatment of glycogen storage disease type Ia (GSDIa): In February 2026, the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) seeking approval of DTX401 as a treatment for GSDIa and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026." https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-206368): "DTX401 (pariglasgene brecaparvovec) AAV8 gene therapy for the treatment of glycogen storage disease type Ia (GSDIa): In February 2026, the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) seeking approval of DTX401 as a treatment for GSDIa, granted the BLA Priority Review, and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026." https://www.sec.gov/Archives/edgar/data/1515673/000119312526206368/rare-ex99_1.htm

### August 23, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: glycogen storage disease type Ia.
- First seen 2026-01-12, last confirmed 2026-08-05.
- SEC Form 8-K (accession 0001193125-26-062568): "The FDA granted the BLA Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026." https://www.sec.gov/Archives/edgar/data/1515673/000119312526062568/rare-20260223.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-332802): "DTX401 (pariglasgene brecaparvovec) AAV8 gene therapy for the treatment of glycogen storage disease type Ia (GSDIa): In February 2026, the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) seeking approval of DTX401 as a treatment for GSDIa and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026." https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-206368): "DTX401 (pariglasgene brecaparvovec) AAV8 gene therapy for the treatment of glycogen storage disease type Ia (GSDIa): In February 2026, the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) seeking approval of DTX401 as a treatment for GSDIa, granted the BLA Priority Review, and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026." https://www.sec.gov/Archives/edgar/data/1515673/000119312526206368/rare-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-333233): "The FDA granted the BLA Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026." https://www.sec.gov/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-048738): "DTX401 (pariglasgene brecaparvovec) AAV8 gene therapy for glycogen storage disease type Ia (GSDIa): Biologics License Application (BLA) rolling submission completed in December 2025, with an anticipated Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/rare-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-009791): "DTX401 (pariglasgene brecaparvovec) AAV gene therapy for glycogen storage disease type Ia (GSDIa): Biologics License Application (BLA) rolling submission completed in December 2025, with an anticipated PDUFA date in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1515673/000119312526009791/rare-ex99_1.htm

Calendar months: [August 2026](https://sec-api.dev/fda-calendar/2026-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pariglasgene-brecaparvovec.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pariglasgene brecaparvovec PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pariglasgene-brecaparvovec

```bibtex
@misc{secapidev_pdufa_pariglasgene_brecaparvovec_20261116,
  title        = {Pariglasgene brecaparvovec PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pariglasgene-brecaparvovec}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pariglasgene_brecaparvovec_20261116","title":"Pariglasgene brecaparvovec PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pariglasgene-brecaparvovec","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
